US20050244358A1 - Use of mixture of sodium hyaluronate and chondroitin sulfate for use in products and therapies for cosmetic surgery - Google Patents

Use of mixture of sodium hyaluronate and chondroitin sulfate for use in products and therapies for cosmetic surgery Download PDF

Info

Publication number
US20050244358A1
US20050244358A1 US11/151,101 US15110105A US2005244358A1 US 20050244358 A1 US20050244358 A1 US 20050244358A1 US 15110105 A US15110105 A US 15110105A US 2005244358 A1 US2005244358 A1 US 2005244358A1
Authority
US
United States
Prior art keywords
chondroitin sulfate
sodium hyaluronate
weight
concentration
method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/151,101
Inventor
Elias Hermida Ochoa
Original Assignee
Hermida Ochoa Elias H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA/A/2001/011542 priority Critical
Priority to MXPA01011542A priority patent/MXPA01011542A/en
Priority to US10/082,743 priority patent/US6906044B2/en
Application filed by Hermida Ochoa Elias H filed Critical Hermida Ochoa Elias H
Priority to US11/151,101 priority patent/US20050244358A1/en
Publication of US20050244358A1 publication Critical patent/US20050244358A1/en
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/26Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/24Materials or treatment for tissue regeneration for joint reconstruction

Abstract

This invention is related to the use of a composition formed by sodium hyaluronate, sodium chondroitin sulfate and botulinum toxin type A for the treatment of dermal lines, and to the use of such composition in the manufacture of a product for such treatment.

Description

  • This application is a continuation of U.S. Ser. No. 10/082,743, filed Feb. 22, 2005, which claims priority form Mexican Application, Serial No. PA/a/2001/011542, filed Nov. 13, 2001.
  • FIELD OF THE INVENTION
  • This invention is related to methods and compositions for cosmetic surgery, and, in particular, the reduction or elimination or dermal lines and wrinkles by means of the subdermal application of a mixture of sodium hyaluronate, and chondroitin sulfate, and botulinum toxin type A.
  • The main objectives of the present invention are to introduce new medical uses of a mixture of sodium hyaluronate and sodium chondroitin sulfate for the treatment of dermal lines, wrinkles, varicose veins and related conditions associated with age and/or exposure, corresponding treatment regimens, and the use of the components in the manufacture of products for such therapies.
  • BACKGROUND OF THE INVENTION
  • Osteoarthritis is a condition that affects many millions of persons throughout the world. Previously, there has been no effective treatment that specifically targets the chondral lesion associated with the condition and promotes the in situ regeneration of cartilage at that site.
  • This disease consists of the gradual degeneration and destruction of the articular cartilage due to traumas, structural deformities of the joints, and overweight. This process thins the cartilage through a phenomenon called apoptosis, or programmed cell death. When the surface area has disappeared due to the thinning, it is considered grade I osteoarthritis; when the tangential surface area has also disappeared, it is characterized as grade II osteoarthritis. There are other levels of
  • The clinical manifestations of the development of the condition are: swelling of the joint, pain, crepitation and functional disability that, gradually and steadily, hinders physical mobility, e.g. the taking of lengthy walks and, depending on the affected joint, forced flexion and extension movements. As the condition worsens, pain begins to limit even minimum efforts and can persist at rest making it difficult to sleep. If the condition persists without correction and/or therapy, the joint is totally destroyed, leading the patient to major replacement surgery with total prosthesis, or to disability.
  • Therapeutic methods for the correction of the articular cartilage lesions that appear during the osteoarthritic disease have been developed, but so far none of them have been able to achieve the regeneration of articular cartilage in situ and in vivo.
  • The prior art methods include the following:
      • a) The application of tendinous, periosteal, fascial, muscular or perichondral grafts.
      • b) The implantation of fibrin or cultured chondrocytes. (Osteochondral Grafts Improve Symptoms but May Increase Risk. Of Ostteoarthritis, medscape.com/con/2000/AAOS/story.cfm).
      • c) The administration of chondrogenic stimulating factors such as “insulin-like growth factors I and TGF-B”.
      • d) Implantation of synthetic matrices, such as collagen and carbon fiber.
      • e) Others, such as electromagnetic fields. (J. Buckwalter, M.D., Van C. Mow, Ph. D. and Anthony Ratcliffe, Ph. D. Journal of the American Academy of Orthopaedic Surgery 1994; 2:192-202).
        All of these have reported minimal and incomplete results with formation of repair, but not regenerative tissue, resulting in a poor quality tissue that can neither support the weighted load nor allow the restoration of an articular function with normal movement.
  • One treatment that has 74% to 90% effectiveness and produces excellent results, similar to that presented in this invention, is the transplantation of cultured autologous chondrocytes. This method of treatment was first reported in 1987 in Sweden and was introduced in 1995 to the United States of America. It consists of taking chondral cellular material from the patient, sending it to a laboratory where it is seeded in a proper medium for its proliferation, and then, once enough volume is achieved (a variable period that may last from weeks to months), transporting it in a special container, and finally implanting it in the damaged tissues to cover their defects. This is an expensive procedure that requires the patient to be in the operating room for the removal of the necessary cellular material, and subsequently for the implantation of the proliferated material. Furthermore, a significant waiting period is needed for the implant to be ready. (VLADIMIR, Bobic, MD AAOS Annual Meeting, Mar. 16, 2000.)
  • Other, more conventional treatments include antiinflammatories, antirheumatics, systemics, physiotherapy, injection of depot steroids and, recently, viscoprotection has emerged.
  • Viscoprotection involves the intraarticular application of commercially available sodium hyaluronate viscoelastic materials such as HYLAN G-F 20, SYNVISC, HYALGAN, ARTZ, etc. The sodium hyaluronate substance does affect the rheology of the synovial fluid, producing an almost immediate sensation of free movement and a marked reduction of pain. It has been proven that the change of the intraarticular fluids attendant to sodium hyaluronate instillation produces a blockage of the nociceptors of subsynovial and capsular tissues and that, in addition to the mechanical factors of the osteochondral pathology, the fluids influence these receptors with their lubricating properties. Thus the change in viscosity of these fluids acts favorably on the painful osteochondral symptoms when sodium hyaluronate is instilled. However, the effect of conventional hyaluronate is temporary because the material remains within the articular chamber for only about 72 hours before it is absorbed and/or metabolized. The residual effects of this substance act on the synovial receptors causing a pain reduction that lasts several weeks and even months. However, this isolated effect is counterproductive for the course of the disease and for the viability of the cartilage because, as it masks the symptoms, the joint is used with more intensity and its destruction is accelerated as the original problem is not corrected and the the damaged articular cartilage is not restored. Recent studies with a 5 year follow-up with these substances indicate that clinical improvement is significant and that it represents a remission factor of painful symptoms, but only for short and medium term. Also, adverse effects, characterized by severe pain, significant synovial effusion, rash and ankle edema, have been reported in at least 7.2% of the treated patients. In no instance has hyaluronate therapy been reported to effect cartilage regeneration and long term success. The need exists, therefore, for an improved approach to cartilage regeneration.
  • As an antecedent to this invention, in 1982, the applicant began applying sodium hyaluronate (SH) to thoroughbred race horses at Hipódromo de las Américas (Las Américas Race Track), in Mexico City, Mexico. The knees and ankles are the most commonly injured joints in these horses. Veterinarians at racetracks in the USA had already used this procedure, observing the beneficial reaction that this viscoelastic material produced in the injured knees of the horses. The applicant considered its use in humans, and conceived of adding some substance to cause the restoration of the damaged surface of the cartilage.
  • The applicant hypothesized that chondroitin sulfate (CS), the most important part of the aggrecan proteoglycans which are the basis of chondral support, might have a repaving effect.
  • In 1996 while visiting Alcon Laboratories in Mexico City, the applicant learned that one of the company's ophthalmic products contained both of the above mentioned substances in a gel suspension (VISCOAT®). The inventor obtained detailed information, including the product monograph for VISCOAT® that states that is has no reported side effects in intraocular use; furthermore, there are ample references from efficacy and safety studies of this product (CILCO, In, Summary of safety and efficacy for Viscoat, 1984). It was then that the applicant decided to use it experimentally in patients with osteoarthritis disorders of all degrees, and subsequently analyze the results.
  • The present study reveals another alternative in the management of osteochondral lesions of the knee through the intraarticular application of a mixture of sodium hyaluronate and sodium chondroitin sulfate. While bound by no theories, it may be that the remarkable effectiveness of this therapy is attributable to the promotion of chondrogenesis synergistically combined with the known benefits of viscoelastic therapy. Implanting an artificial matrix of chondroitin sulfate and sodium hyaluronate may represent an indispensable repair factor, as in it naturally arising chondrocytes can proliferate and restore the continuity of the tissue, regenerating the destroyed cartilage to its original form.
  • With this matrix, the symptomatic evolution is significantly favorable and long lasting due to the regeneration of cartilage at the chondral lesions. No side effects have been reported except in a patient who reported pain and slight swelling at the site of application, which subsided spontaneously in 24 hours; he was given acetaminophen as an analgesic.
  • It must be pointed out that in the most preferred usage the product is administered exactly as it is presented for intraocular use and no change is made in the formulation. A change in presentation with a larger capacity syringe is now being proposed, as the current ophthalmic presentation has 0.5 c.c. and 0.75 c.c. syringes.
  • It must also be pointed out that although this is the same preparation as that used intraocularly, its use for this purpose is totally different as it is applied in a conventional intraarticular manner as an inductor of chondrogenesis, to regenerate the cartilage destroyed by osteoarthritis.
  • As previously mentioned, experimental application of this composition in humans started in 1996, and excellent results have been noted. These were confirmed later by arthroscopic studies (direct view of the articular cartilage through the insertion of a camera into the joint), pathological anatomy and histophysiological studies, all of them consistent with the clinical findings that the regeneration of normal articular cartilage was achieved. This is why this treatment is presented as the only currently available procedure that can offer up to 95% regeneration of articular cartilage damaged by grade I and II osteoarthritis in any joint of the human body.
  • SUMMARY OF THE INVENTION
  • This invention was developed to solve the problem of the previously available techniques related to the treatment of articular cartilage damaged by osteoarthritis.
  • This invention introduces a method to achieve regeneration of the articular cartilage by chondrogenic induction through the intraarticular implantation of an artificial matrix in patients and animals with chondromalacia and/or osteoarthritis in any joint, but preferably in human patients with grade I or II osteoarthritis.
  • The regeneration process is elicited by implanting an artificial matrix formed by a mixture of chondroitin sulfate and hyaluronic acid or pharmaceutically acceptable salts thereof, where naturally arising chondrocytes can settle, and where, as they mature, they form, in groups of 3 or 4, their own definitive hyaline matrix, duplicating the same pattern of the natural cartilage. In this manner the continuity of the articular surface is recovered, mobility is regained, pain is eliminated and thus function is recovered.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • A more complete understanding of the present invention and the advantages thereof may be acquired by referring to the following description, taken in conjunction with the accompanying drawings in which like reference numbers indicate like features and wherein:
  • FIGS. 1 to 6 represent pre- and post implantation arthroscopic images from patients who underwent the treatment of the present invention: macro and microscopic confirmation of regeneration of the articular surface with De Novo cartilage with the same characteristics as the original, a conclusive pathology report, and histophysiology tests (S-100 Protein) both of which confirm the characteristics of the regenerated cartilage.
  • FIGS. 1 and 2 represent pre- and two years post treatment arthroscopic images, respectively.
  • FIG. 3 represents the regeneration of the articular cartilage with De Novo cartilage.
  • FIGS. 4 and 5 are microscopic images that show the maturing of the zone tangential to the superficial layer where fully developed and maturing chondrocytes are found, surrounded by a hyaline matrix.
  • FIG. 6 is a confirmatory histophysiological image with the application of S-100 protein. It shows the reaction of the cartilaginous tissue to this test with a positive result.
  • FIGS. 7 to 15 show the graphical results of the studies conducted and described herein.
  • CHARACTERISTICS OF THE PRODUCT
  • In its preferred embodiment, the chondroitin sulfate/hyaluronate composition of the present invention is presented under the trade name of VISCOAT® (Alcon Laboratories, Inc., Fort Worth, Tex., USA). It is suitable for the treatment of chondral lesions in all osteoarthritis (OA) in patients, and particularly in those who fail to respond adequately to traditional non-drug therapies and plain analgesics.
  • The VISCOAT® product packaging identifies U.S. Pat. Nos. 4,486,416 and 6,051,560, the entire contents of both of which are by this reference incorporated herein. The VISCOAT® product is also registered before the SSA (Mexican Health Secretariat) under registration number Reg SSA Mex. No 0735 C 88.
  • According to the manufacturer provided product information:
    • “VISCOAT® Viscoelastic Solution is a sterile, non-pyrogenic, viscoelastic solution of highly purified, non-inflammatory medium molecular weight sodium chondroitin sulfate and sodium hyaluroante. VISCOAT® is formulated to a viscosity of 40,000±20,000 cps (at shear rate of 2 sec−1, 25° C.). Each 1 mL of VISCOAT® solution contains not more than 40 mg sodium chondroitin sulfate, 30 mg sodium hyaluronate, 0.45 mg monobasic sodium phosphate, monohydrate, 2.00 mg dibasic sodium phosphate anhydrous, 4.3 mg sodium chloride (with Water for Injection, USP grade, q.s.). The osmolarity of VISCOAT® is 325 mOsM±40 mOsM; the pH is 7.2±0.2.
  • Sodium chondroitin sulfate and sodium hyaluronate are quite similar in regard to chemical and physical composition, as each occurs as a large, unbranched chain structure of medium to high molecular weight. The sodium chondroitin sulfate used in the preparation of the VISCOAT® Viscoelastic Solution has a mean molecular weight of approximately 22,500 daltons, while the sodium hyaluronate exhibits a molecular weight of over 500,000 daltons.”
  • This product has a gel presentation that contains a mixture of sodium hyaluronate and chondroitin sulfate; these substances exist in natural form in the human body as part of cartilage, synovial membrane, umbilical cord and vitreous humor of the eye.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The product is applied or instilled by conventional intraarticular means, typically injection, with prior asepsis and antisepsis of the region. This is typically done in the treatment room of the physician's office. The product applied (injected) is called an implant. As previously explained, CS is the most important part of aggrecan, a predominant proteoglycan in articular cartilage. The CS acts with its long chains inserted in the protein nucleus as a support element of the chondral stroma. It is thus that it serves as an artificial matrix that sticks to the bed of the lesion, allowing the migrating, unattached, peripheral chondrocytes of the erosion to settle in it. When they mature, the chondrocytes secrete a definitive hyaline matrix that replaces the temporary one afforded by the viscoelastic composition (“wet nurse”) and thus it regenerates until it manages to recover the original shape and thickness. This has been verified when, upon performing controlled post-implant arthroscopy, cartilage regeneration is observed macroscopically. Microscopically, findings of “De Novo” articular cartilage with normal morphological characteristics, as well as positive histophysiological results to S-100 protein, are reported.
  • The preferred method for this invention's chondrogenic induction is the intraarticular application of a mixture containing 60 mg of CS and 45 mg of SH in a gel suspension, equivalent to 1.5 c.c. of the formulation, when dealing with large joints, and the preferred application of a mixture containing 30 mg of CS and 22.5 of SH in 0.75 cubic centimeters for smaller joints such as the coxofemoral, ankle or elbow joints. The inventor has also determined that for even smaller joints such as the interphalangeal or wrist joints, a mixture containing 20 mg of CS and 15 mg of SH in 0.5 cubic centimeters be used. The number and frequency of administration of the doses of the composition will be similar to those used in conventional viscoprotective therapy regimens, and will be adjusted to suit the needs of the particular patient. Generally, 2 to 6 doses are administered over 1 to 3 months. 2-4 doses administered at 10-20 day intervals are preferred. Most preferred is a regimen of 3 doses at 15 day intervals with subsequent periodic applications every 3, 6, 9, or 12 months, depending on the results. This method produces up to a 94.5% regeneration of the articular cartilage destroyed by grade I and II osteoarthritis, according to the results obtained in the study made on 325 knees and 16 coxofemoral joints.
  • Detailed Description of the compound Used in the Treatment
  • As mentioned previously, it is important to consider that in the most preferred embodiment of the present invention, the product is applied exactly as it is presented for intraocular use, without any changes in the formulation, using a syringe of adequate capacity, for example, a 21×32 sterile hypodermic needle. Concentrations of the chondroitin sulfate and hyaluronate useful for purposes of the invention, however, may range from about 0.1% to about 50% by weight for each such component. The molecular weight of the chondroitin sulfate should be greater than about 20,000 daltons, and preferably between about 20,000 and 50,000 daltons. The molecular weight of the hyaluronate should be at least 500,000 daltons and preferably between about 500,000 and 1,000,000 daltons.
  • In the practice of the invention, sodium hyaluronate may be used at concentrations from about 0.1 g up to about 10 g in 100 ml water at temperatures between about 4° C. and about 37° C. Chondroitin sulfate is also used at concentrations from about 0.1 g up to about 10 g in 100 ml water at temperatures between about 4° C. and about 37° C. Other pharmaceutically acceptable salts, including without limitation magnesium, calcium and potassium chondroitin sulfates and hyaluronates are also useful in the practice of the invention. Within the ranges just described, any quantity of chondroitin sulfate can be added to form binding interaction with hyaluronate and produce physical and flow properties suitable for intraarticular uses. Adding 12.6 g of chondroitin sulfate to 10 g sodium hyaluronate in water, the resulting solution has viscosity of over 1 million centipoises at 25° C. for low shear rate below 50 sec−1). The preferred ratio of chondroitin sulfate to hyaluronate is about 4:3 by weight. Preferred concentrations range from about 0.1% to about 5.3% by weight for the chondroitin sulfate component and from about 0.1% to about 4.2% by weight for the hyaluronate component.
  • The preferred aqueous buffer solution used in the practice of the invention includes monobasic sodium phosphate, dibasic sodium phosphate, and sodium chloride mixed to form an aqueous buffer to maintain pH of about 7 to about 8.0 and osmolarity of 300-350 mOsmol/kg. By raising the buffer concentration of monobasic sodium phosphate and dibasic sodium phosphate, the ionic strength of chondroitin sulfate/ hyaluronate solution is increased. The kinetic rate constant of molecule interaction between chondroitin sulfate and hyaluronate is increased by raising ionic strength and temperature. This invention comprises concentrations of dibasic sodium phosphate and monobasic sodium phosphate from 0.1 g/100 ml to 5 g/100 ml and pH range of 7.0 to 8.0 at reaction temperatures between 4° C. and 40° C. The following example shows the effect of buffer on the viscosity or apparent molecular weight of the mixture for 5.3 g CS/4.2 g SH in 100 ml water:
    • Buffer 1:
      • Diabasic sodium phosphate: 4.5 mg/ml
      • Sodium dihydrogen phosphate hydrate: 1.5 mg/ml
      • Viscosity of composition of the present invention at 1 sec−1 and 25° C. is 68,878 cps.
    • Buffer 2:
      • Dibasic sodium phosphate: 7.5 mg/ml
      • Sodium dihydrogen phosphate hydrate: 1.0 mg/ml
      • Viscosity of compositions of the present invention at 1 sec−1 and 25° C. is 115,011 cps.
  • In a most preferred formulation, i.e. the VISCOAT® formulation, each cubic centimeter of the mixture contains 40 mg of chondroitin sulfate (molecular weight of approximately 22,500 daltons), 30 mg of sodium hyaluronate (molecular weight of approximately 750,000 daltons), 0.45 mg of sodium monobasic monohydrate phosphate, 2 mg of sodium dibasic anhydrous phosphate, 4.3 mg of sodium chloride and water.
  • Tests Performed
  • Type of Studies: Prospective, Longitudinal and Experimental.
  • A study was conducted on 210 patients, 325 knees with chondromalacia and grades I and II osteoarthritis and 16 joints (coxofemoral) with painful articular symptoms and functional limitation, treated previously in a conventional manner with NSAIDs or with steroid injections; the patients were refractory to these treatments.
  • Inclusions Criteria
  • The inclusion criteria during this study were as follows:
  • Patients of both sexes with chronic chondral or osteochondral pathology of the knee and coxofemoral joint up to grade II arthrosis were included, who had no clinical improvement with conventional treatment, no added autoimmune or neoplastic pathologies, of all ages, with prior arthroscopic surgery, without recent management with systemic or articular steroids or nonsteroidal antiinflammatories (NSAIDs).
  • Exclusion Criteria
  • The following exclusion criteria were adopted: patients with grade III or upper gonarthrosis or coxarthrosis, recent or current treatment with systemic or intraarticular steroids, severe deformities and autoimmune or neoplastic pathology.
  • Non-Inclusion Criteria
  • Dropping out of treatment, death, change of medical therapy.
  • The Clinical Assessment was as Follows:
  • Pain: slight, moderate or severe.
  • Gait: occasional claudication, assistance with walking stick or crutches or impossible to walk.
  • Mobility: complete arches, slight, moderate or severe limitation.
  • Synovial effusion: minimum, moderate or severe (occasional or constant). (SCRIPPS SCALE FOR SPECIAL SURGERY)
  • Radiographic Assessment:
  • Radiographic changes, articular clamping, chondromalacia and osteoarthritis. Pre- and posttreatment radiographic studies.
  • Arthroscopic Assessment:
  • Pre- and posttreatment images.
  • Results:
  • 210 patients were treated: 325 knees (115 bilateral (230 knees) and 95 unilateral (95 knees), 144 women (68.5%), 66 men (31.5%), aged 12 to 86 years, a mean of 44.2 years, 48 knees were diagnosed with chondromalacia, 40 with grade I osteoarthritis and 237 with grade II osteoarthritis.
  • Another 16 patients treated: 16 coxofemoral (hip) joints.
  • A visual analog clinical scale (SCRIPPS CLINIC FOR SPECIAL SURGERY) was applied and, as shown in FIG. 7, 309 knees (95.07%) showed immediate significant improvement and satisfactory evolution for up to two years of follow-up, 250 knees (83.3%) remained in the same good conditions without needing to take any NSAID for up to 50 months of follow up, 32 knees (13%) showed moderate pain and 18 cases (6%) showed no short and medium term improvement. Finally, from 16 osteoarthritis coxofemoral (grades I, II, III and IV) (hip) joints, 14 (87.5%) grade I and II coxofemoral joints showed excellent results, and 2 (12.5%) grade III and IV coxofemoral joints, due to the advanced degree of deterioration, did not obtain any positive results.
  • None of the patients had any systemic reactions during this treatment: only one patient reported pain and a slight swelling after the implantation.
  • FIGS. 8-10 show the previously described results.
  • To complement the previous results, a comparative study was conducted on 20 patients treated with NSAIDs due to grade II knee osteoarthritis and 20 patients treated with VISCOAT® for the same reason. The results, after 90 days, were as shown in FIGS. 11 and 12. FIG. 11 shows the results for pain reduction and FIG. 12 the results for increased mobility, each after 90 days.
  • FIG. 13 shows the results after 24 months according to the HSS scale (Scripps Clinics).
  • Doses Applied:
  • The study continued, as shown in FIG. 14, with the application of 3 doses of the composition to 78 knees, which represented 31% of the knees treated; 151 knees received 2 doses which represented 60.4% and 21 knees received only one dose which represented 8.4%. The 28% shown in the graph of FIG. 14 corresponds to 70 patients who, after 6 months, needed up to 8 supplementary doses; this has reduced the index of nocturnal pain, gait pain and pain at rest, and increased the range of mobility.
  • FIG. 15 shows the graphic results of 16 coxofemoral joints, 3 doses covered 87.5% with excellent results in 14 coxofemoral joints treated with the composition, and the 12.5% shown in the graph of FIG. 15 corresponds to the 2 patients with grade III and IV osteoarthritis who did not report any positive results.
  • These applications were made in 9 male and 7 female patients aged 27 to 79 years.
  • Studies and Tests Performed on Patients that Prove Cartilage Regeneration by the Application of the Composition that Contains CS and SH.
  • The following examples are given to illustrate and demonstrate the new use of the composition of this invention.
  • 69 year old female patient treated previously with the composition of sodium hyaluronate and chondroitin sulfate. Biopsy of knee cartilage.
  • Microscopic Description:
  • A histological study of knee cartilage was performed. Its microscopic description was as follows: the sections present fragments of mature cartilage with islands of chondrocyte arranged regularly in groups of 2 to 3, with cohesiveness, and surrounded by a hyaline matrix without laminar fibrosis. The chondrocytes have a round nucleus, clear cytoplasm, and they are morphologically normal and with good maturation. There is no endochondral ossification or dystrophic calcification and, as in the previous example, there is no evidence of malignant neoplasia.
  • Diagnosis: Biopsy of knee cartilage.
  • De Novo cartilage formation, morphologically and architecturally normal.
  • This is confirmed by the image in FIG. 3.
  • 78-year old female patient treated previously with the compound of sodium hyaluronate and chondroitin sulfate. Biopsy of the femoral condylar cartilage.
  • Microscopic Description:
  • A histologic study was made of several irregular tissue fragments that jointly measured 0.5 cm; they had a white pearly color, a firm consistency; they were identified as right and left. Paraffin technique inclusions were made of them.
  • Diagnosis: Biopsy of Femur Condylar Cartilage.
  • Fragment of mature cartilage with partial hyalinization. (Without evidence of malignant neoplasia). See confirmation in the image of FIG. 4.
  • Discussion of the Results Obtained:
  • The functional result subsequent to the implantation of the product was very satisfactory for most of treated patients. The difference between the plain systemic drug management and the intraarticular application of the chondroitin sulfate and sodium hyaluronate implant is very evidently in favor of the latter. It must be considered that the plain intraarticular rheological change (viscosity, elasticity and plasticity) reduces the pain and stimulates a synovial response, changing the viscoelastic features of the fluid. However, the basic difference lies in the medium and long term response which may be effected by the chondrogenic induction provoked by CS and, with it, the permanent solution to the chondral lesion, to the clinical manifestations and the functional disability, as well as to the risk of major surgery.
  • Conclusions:
  • The treatment of osteochondral lesions with intraarticular sodium chondroitin sulfate and sodium hyaluronate has proven to have a significantly favorable clinical response compared with the conventional treatment. This response has been confirmed with pre- and post treatment arthroscopic imaging, conventional and electron microscope examination as well as histophysiology testing (POSITIVE S-100 Protein) showing that the damaged cartilage is regenerated in a period of about 2 years recovering its normal structure and function. The indications for the chondrogenic induction intraarticular treatment are preferably addressed to patients with chondromalacia and grades I and II osteoarthritis in any joint of the human body.
  • The original cause of the osteochondral pathology should invariably be treated, as the long-term result of the procedure will depend on that. Prior surgical management, where indicated, through minimal invasive surgery, is an excellent alternative for the integral management of osteochondral lesions and their better long-term prognosis.
  • Similarly, the methods of the present invention may be used in conjunction with other known therapies. For example, the chondroitin sulfate-hyaluronate mixture of the present invention may be administered to a joint in need thereof in combination with one or more other agents selected from anti-inflammatories, antirheumatics, steroids and chondrogenic stimulating factors, either separately or in a single formulation.
  • Therefore, the mixture of sodium hyaluronate and sodium chondroitin sulfate can be used now in defined amounts in a therapeutically useful manner for all the characterized pathological conditions by the simple intraarticular application route, and the absence of risks of both components makes this therapy particularly attractive.
  • As previously discussed, the viscoelastic compositions of the present invention are known to have utility in ophthalmic surgery. Those skilled in the viscoelastic arts will appreciate, however, that such compositions will have utility beyond ophthalmic and joint therapy as described above. They may be used in a variety of therapies, and especially in drug delivery, cosmetic surgery and reconstructive surgery. The compositions of the present invention are well suited for delivery of anti-fibrotics, antibiotics, steroidal and non-steroidal anti-inflammatories, anesthetics, analgesics and other medicaments or gene therapies to diseased or traumatized tissues in need thereof. Cosmetically, these compositions may be injected to reduce wrinkles or to treat varicose veins. For treatment of dermal lines or wrinkles, these compositions may combined with a muscle relaxing agent such as botulinum toxin type A, commercially available as BOTOX® (Allergan, Inc., Irvine Calif. USA), and injected subdermally in the conventional manner. The presently disclosed compositions and methods may also be used in any environment where there is a need for tissue separation or stabilization and the potential exists for complications, typically post-surgical, arising from tissue fibrosis and/or adhesions. They will be particularly useful in nasal, spinal cord, cardiovascular, orthopoedic and orthodontic surgical procedures that would otherwise be prone to such complications.
  • Those skilled in the art will recognize that the preferred modes may be altered or amended without straying away from the true spirit and scope of the invention as defined in the enclosed claims.

Claims (11)

1. A therapeutic method for reducing dermal lines comprising the subdermal administration in a region associated with the dermal lines of a viscous composition comprising a therapeutically effective amount of a mixture of chondroitin sulfate, hyaluronic acid or pharmaceutically acceptable salts thereof and botulinum toxin type A.
2. The method of claim 1, wherein the dermal lines are on a human patient and the dermal lines are caused by age or exposure .
3. The method of either claim 1 or claim 2, wherein the composition comprises a mixture of chondroitin sulfate at a concentration of 0.1 to 50% by weight and sodium hyaluronate at a concentration of 0.1 to 50% by weight.
4. The method of claim 3, wherein the chondroitin sulfate concentration is from 0.1 to 5.3% by weight and the sodium hyaluronate concentration is from 0.1 to 4.2% by weight of the composition.
5. The method of claim 4, wherein the composition is a sterile, non-pyrogenic, viscoelastic solution comprising a mixture of chondroitin sulfate and sodium hyaluronate in a ratio of about 4 parts by weight chondroitin sulfate to about 3 parts by weight sodium hyaluronate.
6. The method of claim 5, wherein the concentration of chondroitin sulfate is about 40 mg/ml and the concentration of sodium hyaluronate is about 30 mg/ml.
7. The method of claim 6, wherein the chondroitin sulfate has a molecular weight of 20,000 to 50,000 daltons, the sodium hyaluronate has a molecular weight of 500,000 to 1,000,000 daltons, and the composition has a viscosity of 20,000 to 60,000 cps.
8. The method of claim 1, wherein doses of between 0.5 and 1.5 cubic centimeters of the viscoelastic composition are periodically administered to the associated region.
9. The use of stable, viscous, buffered aqueous solution which comprises a mixture of chondroitin sulfate at a concentration of about 0.1 to 50% by weight, sodium hyaluronate at a concentration of about 0.1 to 50% by weight, and a therapeutically effective amount of botulinum toxin type A in the manufacture of a product for the subdermal treatment of dermal lines.
10. The use according to claim 9, wherein said solution is maintained at a pH of about 7.0 to 8.0.
11. The use according to claim 9, wherein the solution has an osmolarity of from about 300 to about 350 mOsmol/kg.
US11/151,101 2001-11-13 2005-06-13 Use of mixture of sodium hyaluronate and chondroitin sulfate for use in products and therapies for cosmetic surgery Abandoned US20050244358A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MXPA/A/2001/011542 2001-11-13
MXPA01011542A MXPA01011542A (en) 2001-11-13 2001-11-13 Regeneration of articular cartilage damaged by osteoarthritis i and ii, by means of intra-articular application of sodium hyaluronate and chondroitin sulphate in a gel carrier.
US10/082,743 US6906044B2 (en) 2001-11-13 2002-02-22 Regeneration of articular cartilage damaged by grade I and II osteoarthritis by means of the intraarticular application of a mixture of sodium hyaluronate and chondroitin sulfate in a gel vehicle
US11/151,101 US20050244358A1 (en) 2001-11-13 2005-06-13 Use of mixture of sodium hyaluronate and chondroitin sulfate for use in products and therapies for cosmetic surgery

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/151,101 US20050244358A1 (en) 2001-11-13 2005-06-13 Use of mixture of sodium hyaluronate and chondroitin sulfate for use in products and therapies for cosmetic surgery

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/082,743 Continuation US6906044B2 (en) 2001-11-13 2002-02-22 Regeneration of articular cartilage damaged by grade I and II osteoarthritis by means of the intraarticular application of a mixture of sodium hyaluronate and chondroitin sulfate in a gel vehicle

Publications (1)

Publication Number Publication Date
US20050244358A1 true US20050244358A1 (en) 2005-11-03

Family

ID=33297421

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/082,743 Active US6906044B2 (en) 2001-11-13 2002-02-22 Regeneration of articular cartilage damaged by grade I and II osteoarthritis by means of the intraarticular application of a mixture of sodium hyaluronate and chondroitin sulfate in a gel vehicle
US10/469,258 Active US6949525B2 (en) 2001-11-13 2002-11-13 Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis
US11/151,101 Abandoned US20050244358A1 (en) 2001-11-13 2005-06-13 Use of mixture of sodium hyaluronate and chondroitin sulfate for use in products and therapies for cosmetic surgery

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/082,743 Active US6906044B2 (en) 2001-11-13 2002-02-22 Regeneration of articular cartilage damaged by grade I and II osteoarthritis by means of the intraarticular application of a mixture of sodium hyaluronate and chondroitin sulfate in a gel vehicle
US10/469,258 Active US6949525B2 (en) 2001-11-13 2002-11-13 Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis

Country Status (16)

Country Link
US (3) US6906044B2 (en)
EP (1) EP1443945B1 (en)
JP (2) JP4741183B2 (en)
KR (1) KR100989109B1 (en)
CN (1) CN1585645A (en)
AT (1) AT411807T (en)
AU (1) AU2002363589B2 (en)
BR (1) BR0214032A (en)
CA (1) CA2466499C (en)
DE (1) DE60229545D1 (en)
DK (1) DK1443945T3 (en)
ES (1) ES2312648T3 (en)
HK (1) HK1064043A1 (en)
MX (2) MXPA01011542A (en)
WO (1) WO2003041724A1 (en)
ZA (1) ZA200402717B (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060099227A1 (en) * 2000-02-08 2006-05-11 Hunt Terrence J Polysaccharide containing botulinum toxin pharmaceutical compositions and uses thereof
US20060104994A1 (en) * 2000-02-08 2006-05-18 Hunt Terrence J Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20070179117A1 (en) * 2004-04-16 2007-08-02 Roland Reiner Injectable crosslinked and uncrosslinked alginates and the use thereof in medicine and in cosmetic surgery
US20080199519A1 (en) * 2004-11-18 2008-08-21 Cellmed Ag Production of Double-or Multi-Layered Microcapsules
US20080213315A1 (en) * 2000-02-08 2008-09-04 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20090155314A1 (en) * 2007-12-12 2009-06-18 Ahmet Tezel Dermal filler
US7579010B2 (en) 2000-02-08 2009-08-25 Allergan, Inc. Botulinum toxin pharmaceutical compositions with a recombinant human serum albumin
US20100129449A1 (en) * 2004-10-01 2010-05-27 First Eric R Cosmetic Neurotoxin Compositions and Methods
US20110097367A1 (en) * 2008-01-16 2011-04-28 Cellmed Ag Monolithic in-situ cross-linked alginate implants
US20120141532A1 (en) * 2007-12-12 2012-06-07 Blanda Wendy M Botulinum Toxin Formulation
US20140044695A1 (en) * 2005-08-01 2014-02-13 Allergan, Inc. Botulinum toxin compositions
US20140349959A1 (en) * 2007-11-30 2014-11-27 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US20150165003A1 (en) * 2013-12-12 2015-06-18 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US20150313973A1 (en) * 2014-04-30 2015-11-05 Allergan, Inc. Formulations of biologics for intravesical instillation
WO2017057824A1 (en) * 2015-09-30 2017-04-06 Sunbio Inc. Polyethylene glycol hydrogel injection

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030086899A1 (en) * 2000-03-14 2003-05-08 Jafari Masoud R. Chondroitin sulfate containing viscoelastics for use in treating joints
US20040101561A1 (en) * 2002-11-13 2004-05-27 Jafari Masoud R. Combinations of viscoelastics for use during surgery
US20040118414A1 (en) 2002-12-20 2004-06-24 Shah Mandar V Surface modified viscoelastics for ocular surgery
US7363928B2 (en) 2001-12-21 2008-04-29 Alcon, Inc. Dilution resistant viscoelastic compositions
US7820194B2 (en) * 2001-12-21 2010-10-26 Alcon, Inc. Combinations of viscoelastics for use during surgery
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US9186375B2 (en) 2007-06-21 2015-11-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan compositions in combination with stem cells
US8455458B2 (en) 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
US7803787B2 (en) * 2002-10-16 2010-09-28 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage by transmucosal administration
US7485629B2 (en) * 2002-10-16 2009-02-03 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treatment of joint damage
US20080003258A1 (en) * 2002-10-16 2008-01-03 Marcum Frank D Composition and Method for Treating Rheumatoid Arthritis
US7504387B2 (en) * 2002-10-16 2009-03-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis
EP1594523B1 (en) * 2002-12-20 2009-03-25 Botulinum Toxin Research Associates, Inc. Pharmaceutical compositions comprising botulinum toxin and human serum albumin
CA2540586A1 (en) * 2003-10-01 2005-04-21 Optimer Pharmaceuticals, Inc. Treatment of a condition in a mammal with administration of aminosugar and uses thereof
CA2541813C (en) 2003-10-09 2011-12-06 Robert John Petrella Methods for treating acute and overuse sprain and strain using hyaluronic acid
US20060003964A1 (en) * 2004-06-30 2006-01-05 Shah Mandar V Dilution resistant viscoelastic compositions
EP1814518A1 (en) * 2004-11-23 2007-08-08 Alcon Inc. Triple natural polymer viscoelastic composition
HUE025255T2 (en) * 2004-12-30 2016-03-29 Genzyme Corp Regimens for intra-articular viscosupplementation
WO2007008206A1 (en) * 2005-07-11 2007-01-18 Alcon, Inc. Dilution resistant viscoelastic compositions
JP4875865B2 (en) * 2005-08-17 2012-02-15 株式会社日本バリアフリー NTx value reducing agent for prevention and treatment of osteoarthritis
ES2281265B1 (en) * 2005-11-24 2008-08-16 Bioiberica, S.A. Compositions for the treatment of osteoarthritis.
ITMI20061030A1 (en) * 2006-05-26 2007-11-27 Altergon Sa New composition comprising glycosaminoglycans in viscosity 'and controlled use of such composition in terapuia of chronic cystitis
TW200743492A (en) * 2006-05-29 2007-12-01 Ching-Chuan Jiang Hyaluronic acid used for purpose of anti-oxidation and proliferation on cartilage cells
ITPD20060219A1 (en) 2006-05-31 2007-12-01 Fidia Farmaceutici Pharmaceutical compositions containing sulphated hyaluronic acid in the treatment of osteoarthritis
CN100417415C (en) 2006-06-28 2008-09-10 文彦春 Soakage of medication for treating arthritis
CN100594029C (en) * 2006-07-24 2010-03-17 凌沛学 Medicinal composition for injections in articular cavity
ES2304886B1 (en) * 2007-04-13 2009-11-11 Bioiberica, S.A. "Compositions joint nourishing".
US8828354B2 (en) 2008-03-27 2014-09-09 Warsaw Orthopedic, Inc. Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US9289409B2 (en) * 2008-04-18 2016-03-22 Warsaw Orthopedic, Inc. Sulindac formulations in a biodegradable material
US8956636B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
US9125917B2 (en) 2008-04-18 2015-09-08 Warsaw Orthopedic, Inc. Fluocinolone formulations in a biodegradable polymer carrier
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US8722079B2 (en) 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US9132119B2 (en) 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US9072727B2 (en) 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US8846068B2 (en) 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US8956641B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US9132085B2 (en) 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US8557273B2 (en) * 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US8197806B2 (en) 2008-06-26 2012-06-12 Kci Licensing, Inc Stimulation of cartilage formation using reduced pressure treatment
US20100015049A1 (en) * 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
US9492375B2 (en) 2008-07-23 2016-11-15 Warsaw Orthopedic, Inc. Foam carrier for bone grafting
US9161903B2 (en) * 2008-10-31 2015-10-20 Warsaw Orthopedic, Inc. Flowable composition that hardens on delivery to a target tissue site beneath the skin
EP2364168A1 (en) 2008-12-04 2011-09-14 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
WO2010078118A2 (en) * 2008-12-30 2010-07-08 Kci Licensing, Inc. Reduced pressure augmentation of microfracture procedures for cartilage repair
US20100226959A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Matrix that prolongs growth factor release
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100239632A1 (en) * 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
IT1393945B1 (en) 2009-04-21 2012-05-17 Fidia Farmaceutici Compositions comprising hyaluronic acid, sulfated hyaluronic acid, calcium and vitamin d3 in the treatment of osteoarticular diseases and musculoskeletal
EP3111891A1 (en) * 2009-07-10 2017-01-04 Kirk Promotion LTD. Prosthetic hip joint
US8617583B2 (en) 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8231891B2 (en) 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
CN101690728B (en) 2009-09-23 2011-09-21 关屹 Composition for treating osteoarthritis
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
US20110097380A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Clonidine formulations having antimicrobial properties
US9504698B2 (en) * 2009-10-29 2016-11-29 Warsaw Orthopedic, Inc. Flowable composition that sets to a substantially non-flowable state
US8597192B2 (en) 2009-10-30 2013-12-03 Warsaw Orthopedic, Inc. Ultrasonic devices and methods to diagnose pain generators
US8758791B2 (en) 2010-01-26 2014-06-24 Warsaw Orthopedic, Inc. Highly compression resistant matrix with porous skeleton
US8475824B2 (en) 2010-01-26 2013-07-02 Warsaw Orthopedic, Inc. Resorbable matrix having elongated particles
US9486500B2 (en) 2010-01-28 2016-11-08 Warsaw Orthopedic, Inc. Osteoimplant and methods for making
US9125902B2 (en) * 2010-01-28 2015-09-08 Warsaw Orthopedic, Inc. Methods for treating an intervertebral disc using local analgesics
US9050274B2 (en) * 2010-01-28 2015-06-09 Warsaw Orthopedic, Inc. Compositions and methods for treating an intervertebral disc using bulking agents or sealing agents
US8246571B2 (en) 2010-08-24 2012-08-21 Warsaw Orthopedic, Inc. Drug storage and delivery device having a retaining member
US8404268B2 (en) 2010-10-26 2013-03-26 Kyphon Sarl Locally targeted anti-fibrotic agents and methods of use
US9414930B2 (en) 2010-10-26 2016-08-16 Kyphon SÀRL Activatable devices containing a chemonucleolysis agent
US8740982B2 (en) 2010-10-26 2014-06-03 Kyphon Sarl Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis
US8623396B2 (en) 2010-12-03 2014-01-07 Warsaw Orthopedic, Inc. Compositions and methods for delivering clonidine and bupivacaine to a target tissue site
WO2012075451A2 (en) 2010-12-03 2012-06-07 Warsaw Orthopedic, Inc. Clonidine and gaba compounds in a biodegradable polymer carrier
US20120142628A1 (en) * 2010-12-07 2012-06-07 Allergan, Inc. Methods for treating crepitus
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US8398611B2 (en) * 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US9060978B2 (en) 2011-01-24 2015-06-23 Warsaw Orthopedic, Inc. Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist
US9717779B2 (en) 2011-01-31 2017-08-01 Warsaw Orthopedic, Inc. Implantable matrix having optimum ligand concentrations
US9592243B2 (en) 2011-04-25 2017-03-14 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for treatment of an injury
US9511077B2 (en) 2011-04-25 2016-12-06 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for wound healing
US9186377B2 (en) 2011-06-03 2015-11-17 Maguire Abbey, Llc Method, composition, and articles for improving joint lubrication
US8623839B2 (en) * 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
US9132194B2 (en) 2011-07-12 2015-09-15 Warsaw Orthopedic, Inc. Medical devices and methods comprising an adhesive sheet containing a drug depot
US9205241B2 (en) 2011-07-12 2015-12-08 Warsaw Orthopedic, Inc. Medical devices and methods comprising an adhesive material
DK2596796T3 (en) 2011-11-24 2014-01-27 Quimera Ingenieria Biomedica S L Complex obtained from hyaluronic acid or a salt thereof and chondroitin sulfate mixtures
ITPD20120098A1 (en) 2012-03-30 2013-10-01 Fidia Farmaceutici "Faramaceutiche new formulations containing chondroitin sulfate and hyaluronic acid derivatives"
US9511018B2 (en) 2012-04-05 2016-12-06 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable matrix
US8735504B2 (en) 2012-05-02 2014-05-27 Warsaw Orthopedic, Inc. Methods for preparing polymers having low residual monomer content
CA2873076A1 (en) 2012-05-10 2013-11-14 The Trustees Of The Stevens Institute Of Technology Biphasic osteochondral scaffold for reconstruction of articular cartilage
FR2991876B1 (en) 2012-06-13 2014-11-21 Vivacy Lab Composition, in aqueous medium, comprising at least one hyaluronic acid and at least one water-soluble salt of sucrose octasulfate
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
EP2886104A1 (en) 2013-12-11 2015-06-24 Patir, Suleyman An intra-articular gel
ITMI20132116A1 (en) 2013-12-18 2015-06-19 Apharm S R L Association of glycosaminoglycans and cyclodextrins
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9764122B2 (en) 2014-07-25 2017-09-19 Warsaw Orthopedic, Inc. Drug delivery device and methods having an occluding member
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
CN105982912A (en) * 2015-03-02 2016-10-05 黄绣川 Pharmaceutical composition containing sodium hyaluronate and chondroitin sulfate
EP3111941A1 (en) 2015-06-30 2017-01-04 Süleyman Patir Compositions comprising chondroitin sulfate for prophylaxis or treatment of damaged articular cartilage

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4713448A (en) * 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
US5099013A (en) * 1985-03-12 1992-03-24 Biomatrix, Inc, Hylan preparation and method of recovery thereof from animal tissues
US5143724A (en) * 1990-07-09 1992-09-01 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US5340579A (en) * 1984-11-20 1994-08-23 Farmaka S.R.L. Method of treating dermatological conditions
US5409904A (en) * 1984-11-13 1995-04-25 Alcon Laboratories, Inc. Hyaluronic acid compositions and methods
US5498606A (en) * 1981-03-02 1996-03-12 Soll; David B. Protection of human and animal cells
US5929050A (en) * 1998-02-27 1999-07-27 Petito; George D. Chondroitin sulfate composition and method for wound treatment
US6051560A (en) * 1986-06-26 2000-04-18 Nestle S.A. Chrondroitin sulfate/sodium hyaluronate composition
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486416A (en) 1981-03-02 1984-12-04 Soll David B Protection of human and animal cells subject to exposure to trauma
SE8501723L (en) * 1985-04-09 1986-10-10 Pharmacia Ab Preparation anvendas to the treatment of joint inflammation
IT1270095B (en) * 1994-09-28 1997-04-28 Ibsa Inst Biochimique Sa Therapeutic compositions of chondroitin sulfate in the form of gels that can be administered orally
IT1291291B1 (en) 1997-04-30 1999-01-07 Chemedica Sa Use of hyaluronic acid and its salts for the preparation of an aqueous solution useful as intra-articular lavage liquid
JP2000072678A (en) * 1998-06-15 2000-03-07 Takeda Chem Ind Ltd Chondropathy preventive and therapeutic agent
WO2000044367A2 (en) 1999-02-01 2000-08-03 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
PT1560588E (en) * 2002-10-16 2012-01-06 Arthrodynamic Technologies Animal Health Division Inc Treatment for traumatic synovitis and damaged articular cartilage

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498606A (en) * 1981-03-02 1996-03-12 Soll; David B. Protection of human and animal cells
US5409904A (en) * 1984-11-13 1995-04-25 Alcon Laboratories, Inc. Hyaluronic acid compositions and methods
US5340579A (en) * 1984-11-20 1994-08-23 Farmaka S.R.L. Method of treating dermatological conditions
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4713448A (en) * 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
US5099013A (en) * 1985-03-12 1992-03-24 Biomatrix, Inc, Hylan preparation and method of recovery thereof from animal tissues
US6051560A (en) * 1986-06-26 2000-04-18 Nestle S.A. Chrondroitin sulfate/sodium hyaluronate composition
US5143724A (en) * 1990-07-09 1992-09-01 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US5929050A (en) * 1998-02-27 1999-07-27 Petito; George D. Chondroitin sulfate composition and method for wound treatment
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060099227A1 (en) * 2000-02-08 2006-05-11 Hunt Terrence J Polysaccharide containing botulinum toxin pharmaceutical compositions and uses thereof
US20060104994A1 (en) * 2000-02-08 2006-05-18 Hunt Terrence J Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20070081960A1 (en) * 2000-02-08 2007-04-12 Allergan, Inc. Pharmaceutical Compositions Containing Botulinum Toxin
US20110152198A1 (en) * 2000-02-08 2011-06-23 Allergan, Inc. Pharmaceutical compositions containing botulinum toxin
US8501196B2 (en) 2000-02-08 2013-08-06 Allergan, Inc. Pharmaceutical compositions containing botulinum neurotoxin
US20080213315A1 (en) * 2000-02-08 2008-09-04 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8216591B2 (en) 2000-02-08 2012-07-10 Allergan, Inc. Pharmaceutical compositions containing botulinum toxin
US7579010B2 (en) 2000-02-08 2009-08-25 Allergan, Inc. Botulinum toxin pharmaceutical compositions with a recombinant human serum albumin
US20090304748A1 (en) * 2000-02-08 2009-12-10 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US7758873B2 (en) 2000-02-08 2010-07-20 Allergan, Inc. Polysaccharide containing botulinum toxin pharmaceutical compositions and uses thereof
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US9302008B2 (en) 2000-02-08 2016-04-05 Allergan, Inc. Pharmaceutical compositions containing botulinum toxin
US20070179117A1 (en) * 2004-04-16 2007-08-02 Roland Reiner Injectable crosslinked and uncrosslinked alginates and the use thereof in medicine and in cosmetic surgery
US8163714B2 (en) 2004-04-16 2012-04-24 Cellmed Ag Injectable crosslinked and uncrosslinked alginates and the use thereof in medicine and in cosmetic surgery
US20100129449A1 (en) * 2004-10-01 2010-05-27 First Eric R Cosmetic Neurotoxin Compositions and Methods
US8647639B2 (en) * 2004-10-01 2014-02-11 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US20080199519A1 (en) * 2004-11-18 2008-08-21 Cellmed Ag Production of Double-or Multi-Layered Microcapsules
US20140044695A1 (en) * 2005-08-01 2014-02-13 Allergan, Inc. Botulinum toxin compositions
US9629904B2 (en) * 2005-08-01 2017-04-25 Allergan, Inc. Botulinum toxin compositions
US20140349959A1 (en) * 2007-11-30 2014-11-27 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US20090155314A1 (en) * 2007-12-12 2009-06-18 Ahmet Tezel Dermal filler
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
US9622957B2 (en) 2007-12-12 2017-04-18 Allergan, Inc. Dermal filler
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
US20120141532A1 (en) * 2007-12-12 2012-06-07 Blanda Wendy M Botulinum Toxin Formulation
US20110097367A1 (en) * 2008-01-16 2011-04-28 Cellmed Ag Monolithic in-situ cross-linked alginate implants
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US20150165003A1 (en) * 2013-12-12 2015-06-18 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US20150313973A1 (en) * 2014-04-30 2015-11-05 Allergan, Inc. Formulations of biologics for intravesical instillation
US9943576B2 (en) * 2014-04-30 2018-04-17 Allergan, Inc. Formulations of biologics for intravesical instillation
WO2017057824A1 (en) * 2015-09-30 2017-04-06 Sunbio Inc. Polyethylene glycol hydrogel injection

Also Published As

Publication number Publication date
AT411807T (en) 2008-11-15
WO2003041724A1 (en) 2003-05-22
DK1443945T3 (en) 2009-01-12
US20040082540A1 (en) 2004-04-29
MXPA01011542A (en) 2003-05-22
DE60229545D1 (en) 2008-12-04
JP2005515181A (en) 2005-05-26
BR0214032A (en) 2004-10-13
ES2312648T3 (en) 2009-03-01
JP4741183B2 (en) 2011-08-03
CN1585645A (en) 2005-02-23
KR20050044415A (en) 2005-05-12
US6949525B2 (en) 2005-09-27
JP2011105741A (en) 2011-06-02
HK1064043A1 (en) 2008-12-19
EP1443945A1 (en) 2004-08-11
ZA200402717B (en) 2005-02-23
EP1443945B1 (en) 2008-10-22
US6906044B2 (en) 2005-06-14
CA2466499C (en) 2011-10-18
KR100989109B1 (en) 2010-10-25
CA2466499A1 (en) 2003-05-22
US20040214793A1 (en) 2004-10-28
MXPA04004452A (en) 2004-08-11
AU2002363589B2 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
Saito et al. Intra-articular administration of platelet-rich plasma with biodegradable gelatin hydrogel microspheres prevents osteoarthritis progression in the rabbit knee
Buckwalter et al. Articular cartilage repair and transplantation
Michael et al. The epidemiology, etiology, diagnosis, and treatment of osteoarthritis of the knee
Kon et al. Platelet-rich plasma: intra-articular knee injections produced favorable results on degenerative cartilage lesions
Gooding et al. A prospective, ranomised study comparing two techniques of autologous chondrocyte implantation for osteochondral defects in the knee: periosteum covered versus type I/III collagen covered
CN1471412B (en) Composition for the repair and regeneration of cartilage and other tissues and uses of the composition
CA2131021C (en) Use of injectable biomaterials for the repair and augmentation of the anal sphincters
JP3191937B2 (en) Bone induction pharmaceutical preparations
DE69924006T2 (en) An injectable hyaluronic acid derivative with pharmaceuticals / cell
Clouet et al. From osteoarthritis treatments to future regenerative therapies for cartilage
AU2003285198B2 (en) Collagen-based materials and methods for treating synovial joints
US9814580B2 (en) Joint repair using mesenchymal stem cells
Gerwin et al. Intraarticular drug delivery in osteoarthritis
EP1465558B1 (en) Use of cross-linked collagen for intervertebral disc treatment
Jang et al. Platelet-rich plasma (PRP) injections as an effective treatment for early osteoarthritis
US8580289B2 (en) Tissue matrix system
US8137685B2 (en) Hyaluronic acid compound, hydrogel thereof and joint treating material
US20060040894A1 (en) Compositions and methods using hyaluronic acid
Buckwalter et al. Instructional course lectures, the American Academy of orthopaedic surgeons-articular cartilage. Part II: Degeneration and osteoarthrosis, repair, regeneration, and transplantation
Gardner The nature and causes of osteoarthrosis.
Guo et al. Repair of osteochondral defects with biodegradable hydrogel composites encapsulating marrow mesenchymal stem cells in a rabbit model
Williams Achilles tendon lesions in sport
Simon et al. Articular cartilage: injury pathways and treatment options
Musumeci et al. New perspectives for articular cartilage repair treatment through tissue engineering: A contemporary review
Maas et al. Complications of Inject able Synthetic Polymers in Facial Augmentation

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION